Rare condition

Congenital high airway obstruction syndrome

ORPHA:700286 ↗Clinical syndrome

Search all Congenital high airway obstruction syndrome trialsAlert me when a trial opens

studies recruiting now

as of 7 Sept 2026

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No recruiting trial found right now.

1 study is registered for Congenital high airway obstruction syndrome, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.

Alert me when one opens Check expanded access Trials not yet recruiting Recently completed studies Find patient organisations Specialist centres and registries

Keep watching

Get an email when a new Congenital high airway obstruction syndrome study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:700286 ↗

About Congenital high airway obstruction syndrome

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Orphanet expert page ↗GARD (NIH) ↗

Treatments being studied

43 approved treatments and 197 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Revefenacin (Yupelri)Approved: Glycopyrronium Bromide (Cuvposa)Approved: Fluticasone Propionate (Aerivio spiromax)Approved: Beclomethasone (Beclometason)Approved: TiotropiumApproved: Fluticasone Furoate (Alisade)Approved: Fluorometholone (Fluaton)Approved: AlmitrineApproved: VilanterolApproved: Formoterol (Oxis)Approved: Olodaterol (Striverdi respimat)Approved: Aclidinium Bromide (Aclidinium bromide component of duaklir pressair)Approved: Carbocysteine (Loviscol)Approved: Roflumilast (Daliresp)Approved: Formoterol Fumarate (Atimos modulite)Approved: Prasterone (Dhea)Approved: Umeclidinium Bromide (Incruse ellipta)Approved: Formoterol Fumarate HydrateApproved: Theophylline (Accurbron)Approved: Budesonide (Aircort)Approved: UmeclidiniumApproved: Indacaterol Maleate (Arcapta neohaler)Approved: Ipratropium Bromide (Atrovent)Approved: Prednisolone Sodium Phosphate (Codelsol)Approved: ArformoterolApproved: Albuterol Sulfate (Accuneb)Approved: Tiotropium Bromide (Braltus)Approved: IndacaterolApproved: Olodaterol Hydrochloride (Striverdi respimat)Approved: SalmeterolApproved: AclidiniumApproved: Meprednisone (Betapar)Approved: Azithromycin (Azasite)Approved: Salmeterol Xinafoate (Salmeterol xinafoate component of advair)Approved: Arformoterol Tartrate (Brovana)Approved: Vilanterol Trifenatate (Vilanterol trifenatate component of anoro ellipta)Approved: Albuterol (Aerolin)Approved: Pregabalin (Alzain)Approved: BamifyllineApproved: GlycopyrroniumApproved: BitolterolApproved: Beclomethasone Dipropionate (Aerobec 100)Approved: Glycopyrronium Tosylate (Qbrexza)

Phase 3Depemokimab

Phase 3Infliximab (Flixabi)

Phase 3Tezepelumab (Tezspire)

Phase 3Sibenadet

Phase 3Benralizumab (Fasenra)

Phase 3Magnesium Sulfate (Mag sulf)

Phase 3Dupilumab (Dupixent)

Phase 3Metformin

+ 189 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).